Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The review of literature presents the basic principles of treatment of arteril hypertension in patients with chronic kidney disease. The possibilities of combination therapy with dihydropyridine calcium antagonist lercanidipine and third-generation ACE inhibitor enalapril. Presented studies showing nephroprotective properties of each of the drugs included in the fixed combination in patients with nephropathy. Lercanidipine is highly lipophilic and vazoselektivnost proved its clinical efficacy in patients with proteinuria and decreased kidney function. Given in the literature demonstrating the combination of lercanidipine + enalapril. This combination makes it possible to achieve a more pronounced reduction in blood pressure, including elderly patients, patients with diabetes and obesity. The combination of pharmacological effects of lercanidipine and enalapril, creates additional opportunities for organo and reduce the risk of side effects of therapy.
 ...
PMID:[Treatment of arteril hypertension in patients with chronic kidney disease: a fixed combination of lercanidipine and enalapril]. 2480 Apr 84